Not exact matches
The convergence of several factors explains the trend: cheaper genetic
sequencing technologies, the discovery of new oncogenes (genes that can cause a normal cell to become cancerous), a new
generation of computers and bioinformatics that can analyze vast amounts of data, and a multibillion - dollar
effort by researchers inside and outside the pharma industry to develop targeted drugs and companion diagnostics for cancer.
With the
effort to
sequence the entire human genome speeding toward completion, some researchers are now focusing their energy on developing the next
generation of tools that can be used to extract...
Sparked from the
efforts of the T2D - GENES Consortium (Type 2 Diabetes Genetic Exploration by Next -
generation sequencing in multi-Ethnic Samples; T2D - GENES) to aggregate and share results from large - scale T2D
sequence and genotype datasets, the prototype T2D KP was built with seed funding from the NIDDK via the T2D - GENES Consortium and the Slim Initiative for Genomic Medicine in the Americas for T2D (SIGMA T2D).
The CNAG - CRG makes
efforts to promote the utilization of next -
generation sequencing technology for rare disease applications.
Next -
generation genome
sequence data are essential for these
efforts.